JP5751965B2 - 血清に基づく溶液中のインターロイキン６の安定化 - Google Patents

血清に基づく溶液中のインターロイキン６の安定化 Download PDF

Info

Publication number
JP5751965B2
JP5751965B2 JP2011160394A JP2011160394A JP5751965B2 JP 5751965 B2 JP5751965 B2 JP 5751965B2 JP 2011160394 A JP2011160394 A JP 2011160394A JP 2011160394 A JP2011160394 A JP 2011160394A JP 5751965 B2 JP5751965 B2 JP 5751965B2
Authority
JP
Japan
Prior art keywords
serum
ttab
compound
composition
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011160394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012025749A (ja
JP2012025749A5 (https=
Inventor
シュナイダー クリスティアン
シュナイダー クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2012025749A publication Critical patent/JP2012025749A/ja
Publication of JP2012025749A5 publication Critical patent/JP2012025749A5/ja
Application granted granted Critical
Publication of JP5751965B2 publication Critical patent/JP5751965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2011160394A 2010-07-24 2011-07-22 血清に基づく溶液中のインターロイキン６の安定化 Active JP5751965B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10007718A EP2415461B1 (en) 2010-07-24 2010-07-24 Stabilization of interleukin 6 in serum based solutions
EP10007718.9 2010-07-24

Publications (3)

Publication Number Publication Date
JP2012025749A JP2012025749A (ja) 2012-02-09
JP2012025749A5 JP2012025749A5 (https=) 2013-09-05
JP5751965B2 true JP5751965B2 (ja) 2015-07-22

Family

ID=43063518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011160394A Active JP5751965B2 (ja) 2010-07-24 2011-07-22 血清に基づく溶液中のインターロイキン６の安定化

Country Status (4)

Country Link
US (1) US8377882B2 (https=)
EP (1) EP2415461B1 (https=)
JP (1) JP5751965B2 (https=)
ES (1) ES2398646T3 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3605097B1 (en) * 2017-03-27 2024-11-13 NH Foods Ltd. Substance that prevents antigen-antibody reaction inhibition by body fluid
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
CN113614477B (zh) 2019-03-14 2023-04-28 泰尔茂比司特生物技术有限公司 冷冻干燥装载托盘组件及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
DE3939706C1 (https=) 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
DE4022878A1 (de) 1990-07-18 1992-01-23 Boehringer Mannheim Gmbh Konservierung von diagnostischen tests
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
US20050089918A1 (en) * 1998-02-23 2005-04-28 Amersham Biosciences Uk Limited In-situ cell extraction and assay method
KR100771294B1 (ko) * 1999-12-14 2007-10-29 써모 바이오스타, 인크. 폴리펩티드 및 항원 안정화 희석제
EP2236618A3 (en) * 2001-01-31 2011-06-08 Asahi Kasei Pharma Corporation Compositions for assaying glycoprotein
JP4453999B2 (ja) * 2001-02-14 2010-04-21 栄研化学株式会社 尿中蛋白及びペプチドの安定化方法
US7601491B2 (en) 2003-02-06 2009-10-13 Becton, Dickinson And Company Pretreatment method for extraction of nucleic acid from biological samples and kits therefor
MXPA05001815A (es) 2004-02-20 2005-08-24 Hoffmann La Roche Adsorcion de acidos nucleicos a una fase solida.
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
DE602006005806D1 (de) 2006-07-28 2009-04-30 Vista Ventures Gmbh Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten
WO2009048962A1 (en) 2007-10-12 2009-04-16 Vladislav Dolnik Capillary sieving electrophoresis with a cationic surfactant for size separation of proteins
CN102089319B (zh) * 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法

Also Published As

Publication number Publication date
EP2415461A8 (en) 2012-04-04
JP2012025749A (ja) 2012-02-09
ES2398646T3 (es) 2013-03-20
EP2415461B1 (en) 2012-10-31
US20120107953A1 (en) 2012-05-03
US8377882B2 (en) 2013-02-19
EP2415461A1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
KR101042660B1 (ko) 안정한 액체 인터페론 제제
EP2968434B1 (en) C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).
EA029215B1 (ru) Стабильные водные составы адалимумаба
UA126900C2 (uk) Антитіловмісний препарат
AU2018308773B2 (en) IL-15 protein complex pharmaceutical composition and uses thereof
JP2023126930A (ja) 治療用タンパク質の凍結乾燥医薬配合物のためのプロセス
EP0988861A1 (en) Stabilized protein compositions
JP5751965B2 (ja) 血清に基づく溶液中のインターロイキン６の安定化
EP2729164A2 (en) Formulations that stabilize proteins
Lentini et al. Neutrophils discriminate live from dead bacteria by integrating signals initiated by Fprs and TLRs
US20250339536A1 (en) Biopharmaceutical formulations including polymer excipients
US20180028593A1 (en) Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
EP4259192A1 (en) Stable aqueous buffer free formulation of an integrin antibody
JP3470135B2 (ja) 成長ホルモンの結晶体を製造する方法およびそれにより得られる結晶体
KR102917813B1 (ko) 수성 약학 제제
JP7755766B2 (ja) 抗ｉｌ－６抗体製剤
JP2024534206A (ja) 免疫チェックポイント阻害剤の医薬製剤
JP3992792B2 (ja) 血液凝固時間測定用溶液試薬および血液凝固時間測定用溶液試薬用乾燥組成物
JP2021521168A (ja) 安定な抗体製剤
WO2002072135A1 (en) LIQUID INTERFERON α PREPARATIONS FOR INJECTION AND METHOD OF STABILIZING THE SAME
WO2024257040A1 (en) Composition and stable liquid formulations comprising humanized anti-human interleukin 6 (il-6) receptor monoclonal antibodies
US20240366757A1 (en) Formulations of immune check point inhibitors or like
KR20250071252A (ko) 저 투여량 il-6 제형 및 이의 사용 방법
CN112986576A (zh) 从δg的浓度依赖性来测定蛋白质聚集
EP1545583A1 (en) Methods and preparations for curing critically ill patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150519

R150 Certificate of patent or registration of utility model

Ref document number: 5751965

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250